Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
October 2012, Vol 3, No 7
October 2012, Vol 3, No 7
Continuation of Bevacizumab Beyond Progression Improves Outcome in Patients with Metastatic Colorectal Cancer
By
Caroline Helwick
ESMO 2012 Conference
,
ESMO
October 2012, Vol 3, No 7
Vienna, Austria—More support for the continuation of treatment with bevacizumab beyond disease progression in patients with metastatic colorectal cancer was reported at the 2012 European Society for Medical Oncology (ESMO) Congress, validating a small but growing body of previous data.
Read Article
FDA Approved Abraxane for First-Line Therapy of Non–Small-Cell Lung Cancer
FDA Approvals, News & Updates
October 2012, Vol 3, No 7
“Non–small cell is the most common type of lung cancer, the leading cause of cancer death in the United States,” said Mark A. Socinski, MD, Director, Lung Cancer Section, Division of Hematology/Oncology, University of Pittsburgh, and lead investigator of phase 2 and phase 3 clinical trials of paclitaxel protein-bound in lung cancer.
Read Article
Pertuzumab a New Therapeutic Option for Patients with HER2-Positive Metastatic Breast Cancer
By
Alice Goodman
Drug Updates
October 2012, Vol 3, No 7
Pertuzumab, the third HER2-targeted agent with a unique mechanism of action, was approved in July 2012 by the FDA for the treatment of metastatic HER2-positive breast cancer in combination with trastuzumab plus docetaxel.
Read Article
Telemedicine Saves Time, Resources for Palliative Radiotherapy
By
Rosemary Frei, MSc
Economics & Value
,
Economics of Cancer Care
October 2012, Vol 3, No 7
Montreal, Canada—Telemedicine reduces time spent on new-patient consultations for palliative radiotherapy, according to a study presented at the 2012 World Cancer Congress.
Read Article
First Analysis of Medicare Costs Associated with Head and Neck Cancers
Economics & Value
,
Economics of Cancer Care
October 2012, Vol 3, No 7
Toronto, Canada—The first-ever analysis of Medicare payments for head and neck tumors shows that comorbidities and treatment choices are the primary drivers of the costs of each type of cancer; the study results were presented at the 2012 International Conference on Head and Neck Cancer.
Read Article
Integrative Medicine Cuts Inpatient Costs in Oncology Care Unit
By
Rosemary Frei, MSc
Economics & Value
,
Economics of Cancer Care
October 2012, Vol 3, No 7
Albuquerque, NM—Using yoga and other integrative medicine and complementary therapies can cut oncology-related inpatient costs by more than $150 per day as a result of the reduced need for pain medications, anxiolytics, and antiemetics, according to a recent study conducted at the Beth Israel Medical Center in New York City.
Read Article
Companion Drug Testing Is Becoming Critical to Pharmacy Benefits Management
By
Caroline Helwick
October 2012, Vol 3, No 7
Houston, TX—With the onslaught of drugs that will target genetic subsets of patients, companion diagnostic testing will become vitally important, said Jane F. Barlow, MD, MPH, MBA, Vice President of Clinical Innovation, Medco Health Solutions (now Express Scripts), New York, who spoke on personalized medicine during the 2012 Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Evolving Strategies for Cost-Effective Cancer Management
October 2012, Vol 3, No 7
Houston, TX—A wealth of new agents and abundant clinical trial data supporting their use have led to multiple “acceptable” evidence-based options for treating tumors.
Read Article
Health Plans Need Policies for Dealing with Off-Label Drug Use
By
Caroline Helwick
October 2012, Vol 3, No 7
Houston, TX—To eliminate coverage inconsistencies and enhance relationships with providers, health plans should have specific policies for dealing with off-label use of oncologic drugs, said Kristen M. Reimers, RPh, Specialty Pharmacy Director and Clinical Operations Manager for Excellus Health Plans.
Read Article
Fewer Therapy Delays with Palonosetron than with Similar Antiemetics
Breast Cancer Symposium
October 2012, Vol 3, No 7
San Francisco, CA—An analysis of a large claims database showed that patients with breast cancer had fewer delays in chemotherapy and maintained better adherence to their regimens when treated with the 5-hydroxytryptamine 3 (5-HT3) receptor antagonist palonosetron (Aloxi) than with other agents in this antiemetic class.
Read Article
Page 1 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma